Effect of IOP Lowering on Progressive HM

High Myopia Clinical Trial

Official title:

Effect of Medically Intraocular Pressure Lowering on Progressive High Myopia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05850936
• Other study ID #: 2023KYPJ110
• Status: Recruiting
• Phase: N/A
• Start date: June 1, 2023
• Est. completion date: April 30, 2025

Study information

• Verified date: September 2023
• Source: Sun Yat-sen University
• Contact: Xiulan Zhang, MD, PhD
• Phone: +86 13570166308
• Email: zhangxl2[@]mail.sysu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Currently, whether and when intraocular pressure (IOP) lowering medication should be used in progressive high myopia (HM) to control axial elongation is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the growth of axial length in progressive HM eyes.

Description:

Myopia has emerged as a major health issue in east Asia, especially the sight-threatening complications associated with high myopia (HM). Complication of HM can be associated with significant ocular morbidities including maculopathy, retinal detachment, and glaucoma. Previous studies have shown that adult patients with HM have sustained growth of the axial length (AL), which is a risk factor for the progression of pathological myopia and thus may further affect the visual function , so how to slow down the sustained growth of the AL in adult patients with HM has become an urgent clinical problem. Previous studies have shown that IOP-lowering treatment is a protective factor for the growth of the AL in HM , and the results of animal experiments have further shown that medically IOP-lowering treatment can significantly slow down the AL lengthening and refractive changes in the guinea pig model of myopia. On this basis, the investigators proposed in a previous article that medically IOP-lowering treatment may slow down the growth of AL by three pathways related to the sclera and choroid: for the sclera, IOP-lowering treatment may reduce the scleral distending force, slow down the rate of scleral distension, and inhibit the activation of scleral fibroblasts to reduce scleral remodeling; for the choroid, IOP-lowering treatment may increase choroidal blood perfusion and for the choroid, hypotensive treatment can increase choroidal perfusion and thus reduce scleral remodeling due to scleral hypoxia. A previous retrospective study conducted by the investigators also shows that medically IOP-lowering treatment could control the progression of AL in HM, but there is still a lack of evidence from relevant robust randomized controlled clinical trials (RCT). The investigators propose to conduct a RCT to evaluate whether medically IOP-lowering therapy is effective in controlling the progression of AL in HM. Secondly, this study also aims to provide data to evaluate IOP-lowering treatment effects on the incidence of changes in the visual field (VF), optic nerve head morphology including the retinal nerve fiber layer (RNFL), and retinal ganglion cell-inner plexiform layer (GC-IPL) loss, progression of myopic maculopathy, loss in visual function and change in quality of life. The outcomes of this study may provide a strong basis for treatment recommendations to control the progression of high myopic eyes, and to provide high-quality clinical research evidence for international clinical guidelines on myopia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 152
• Est. completion date: April 30, 2025
• Est. primary completion date: April 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Informed consent given, and consent form signed.

2. Age between 18 and 65 years.

3. Diagnosed with HM: spherical equivalent = -6.00 diopters or AL = 26.5 mm.

4. Progressive HM: progression in AL =0.05mm in the past 6 months or =0.1mm in the past 12 months.

5. IOP = 10 mmHg and = 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry .

6. Best corrected visual acuity (BCVA) = 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination.

Exclusion Criteria:

1. Allergic to any kind of IOP-lowering therapy.

2. Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc.

3. Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis.

4. Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye.

5. Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery.

6. Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment.

7. Pregnant or lactating women, or those who plan to have children during the follow-up period.

Related Conditions & MeSH terms

• Glaucoma
• Glaucoma, Suspect
• High Myopia
• Myopia
• Ocular Hypertension

Intervention

Drug:
• Assigned Interventions: IOP-lowering eye drops
IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the first choice for treatment. If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added; If the IOP reduction of 10% is then not achieved at 1 month after adding Brinzolamide 1%, Alphagan 0.2% or Alphagan-P 0.15% eye drops will be added. If an individual is allergic to Xalacom or feels uncomfortable, the eye drops will be switched to Azarga eye drops (combination drops, fixed Brinzolamide with Timolol); If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added. The effect of IOP lowering would be assessed every week after applying each medication until the target IOP was achieved and follow up the schedule time. If an IOP reduction of 10% is then not achieved, the individual will be excluded from the study.

Locations

Country	Name	City	State
China	Zhongshan Ophthalmic Center, Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

References & Publications (3)

Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald — View Citation

Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999 Nov;106(11):2144-53. doi: 10.1016/s0161-6420(99)90497-9. — View Citation

Leske MC, Hyman L, Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure r — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression of axial length (AL)	The number of subjects whose AL progressed during the follow up	12 months
Secondary	Incidence of visual field (VF) defects or progression	The number of subjects whose VF defects progressed during the follow up	12 months
Secondary	Incidence of changes in the optic nerve head morphology including the retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GCIPL)	The number of subjects whose optic nerve head morphology including the RNFL and GCIPL changed during the follow up	12 months
Secondary	progression of myopic maculopathy	The number of subjects whose myopic maculopathy progressed during the follow up	12 months
Secondary	change of quality of life (EQ-5D-5L)	The number of subjects whose EQ-5D-5L changed during follow up	12 months